3D Medicines Inc. (1244.HK)
HKD 3.56
(1.42%)
HKD 3.56
(1.42%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -144.41 Million | -278.77 Million | -377.07 Million | -278.32 Million |
| Net Income | -562.46 Million | -1.05 Billion | -1.46 Billion | -635.38 Million |
| Depreciation & Amortization | 25.46 Million | 21.6 Million | 12.59 Million | 3.37 Million |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 298.96 Million | 141.69 Million | 164.66 Million | 416 Thousand |
| Change in working capital | 110.98 Million | -7.35 Million | -39.87 Million | 21.81 Million |
| Other non-cash items | 1.24 Million | 653.05 Million | 943.18 Million | 325.68 Million |
| Investing Cash Flow | -187.57 Million | -242.1 Million | -98.87 Million | -20.48 Million |
| Investments in PPE | -6.32 Million | -53.98 Million | -56.37 Million | -11.14 Million |
| Acquisitions | - | - | - | -11.11 Million |
| Investment purchases | -426.13 Million | -764.54 Million | -100 Million | - |
| Sales/Maturities of investments | 238.45 Million | 570.34 Million | 50.42 Million | 6.17 Million |
| Other Investing Activities | -181.25 Million | -188.12 Million | 6 Million | -6 Million |
| Financing Cash Flow | 304.51 Million | 408.41 Million | 840.08 Million | 607.38 Million |
| Debt repayment | -93.18 Million | -129.9 Million | -3.52 Million | -133.38 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | -5.75 Million | -37 Thousand | -236.88 Million | -29.88 Million |
| Common Stock Issuance | 219.22 Million | 315.12 Million | 6.01 Million | - |
| Other Financing Activities | 19.65 Million | 271 Thousand | -525.68 Million | 733.56 Million |
| Accounts receivables | 72.7 Million | -13.06 Million | -65.13 Million | - |
| Accounts payables | - | - | - | - |
| Inventory | -3.41 Million | -1.18 Million | -13 Thousand | - |
| Other working capital | -14.32 Million | -5.24 Million | 23.94 Million | 35.07 Million |
| Cash at beginning of period | 696.74 Million | 774.3 Million | 414.26 Million | 112.15 Million |
| Cash at end of period | 666.47 Million | 696.74 Million | 774.3 Million | 414.26 Million |
| Capital Expenditure | -6.32 Million | -53.98 Million | -56.37 Million | -11.14 Million |
| Effect of forex changes on cash | -2.78 Million | 34.9 Million | -4.08 Million | -6.47 Million |
| Net cash flow / Change in cash | -30.26 Million | -77.56 Million | 360.04 Million | 302.1 Million |
| Free Cash Flow | -150.73 Million | -332.76 Million | -433.45 Million | -289.47 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -51.75 Million | -51.75 Million | -173.1 Million | -562.46 Million | -173.1 Million | -89.24 Million |
| Depreciation & Amortization | 7.77 Million | 7.77 Million | 5.55 Million | 25.46 Million | 5.52 Million | 7.15 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 8.2 Million | 8.2 Million | 95.1 Million | 298.96 Million | 95.1 Million | 54.37 Million |
| Change in working capital | -22.56 Million | -22.56 Million | 84.35 Million | 110.98 Million | 84.35 Million | -56.87 Million |
| Other non-cash items | -31.48 Million | -31.48 Million | -59 Thousand | 1.24 Million | -34 Thousand | 531.5 Thousand |
| Investing Cash Flow | 6.51 Million | 6.51 Million | -81.42 Million | -187.57 Million | -81.42 Million | -12.36 Million |
| Investments in PPE | -22.96 Million | -22.96 Million | -377 Thousand | -6.32 Million | -377 Thousand | -2.78 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -426.13 Million | - | - |
| Sales/Maturities of investments | - | - | - | 238.45 Million | - | - |
| Other Investing Activities | 29.47 Million | 29.47 Million | -81.04 Million | -181.25 Million | -81.04 Million | -9.57 Million |
| Financing Cash Flow | -6.14 Million | -6.14 Million | 114.11 Million | 304.51 Million | 114.11 Million | 38.14 Million |
| Debt repayment | - | - | - | -93.18 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -80 Thousand | -80 Thousand | -21.5 Thousand | -5.75 Million | -21.5 Thousand | - |
| Common Stock Issuance | - | - | - | 219.22 Million | - | - |
| Other Financing Activities | -6.06 Million | -6.06 Million | 114.13 Million | 19.65 Million | 114.13 Million | 38.14 Million |
| Accounts receivables | -16.15 Million | -16.15 Million | 63.8 Million | 72.7 Million | 63.8 Million | -27.45 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -1.71 Million | -1.71 Million | 1.61 Million | -3.41 Million | 1.61 Million | -3.32 Million |
| Other working capital | -4.7 Million | -4.7 Million | 18.93 Million | -14.32 Million | 18.93 Million | -26.09 Million |
| Cash at beginning of period | - | - | - | 696.74 Million | - | - |
| Cash at end of period | -88.88 Million | -88.88 Million | 41.34 Million | 666.47 Million | 41.34 Million | -56.47 Million |
| Capital Expenditure | -22.96 Million | -22.96 Million | -377 Thousand | -6.32 Million | -377 Thousand | -2.78 Million |
| Effect of forex changes on cash | 580.5 Thousand | 580.5 Thousand | -3.2 Million | -2.78 Million | -3.2 Million | 1.8 Million |
| Net cash flow / Change in cash | -88.88 Million | -88.88 Million | 41.34 Million | -30.26 Million | 41.34 Million | -56.47 Million |
| Free Cash Flow | -112.79 Million | -112.79 Million | 11.47 Million | -150.73 Million | 11.47 Million | -86.84 Million |
0L35
DGICB
CERA
ATL
SWARAJENG
BPAC11